European Commission grants approval of Ogsiveo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Subscribe To Our Newsletter & Stay Updated